Chemogenomic profiling of anti-leishmanial efficacy and resistance in the related kinetoplastid parasite Trypanosoma brucei
(2019).
Chemogenomic profiling of anti-leishmanial efficacy and resistance in the related kinetoplastid parasite Trypanosoma brucei.
[Dataset].
European Nucleotide Archive.
https://www.ebi.ac.uk/ena/data/view/PRJEB31973
The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by emergent resistance and toxicity. Our understanding of drug mode-of-action and potential routes to resistance is also limited. Forward genetic approaches have revolutionised our understanding of drug mode-of-action in the related kinetoplastid parasite, Trypanosoma brucei. Therefore, we screened our genome-scale T. brucei RNAi library for knockdowns that render cells resistant to the current anti-leishmanial drugs, sodium stibogluconate (antimonial), paromomycin, miltefosine and amphotericin-B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource.
Additional Information
Secondary ID: ERP114591
Keywords
Leishmaniasis| Item Type | Dataset |
|---|---|
| Capture method | Experiment |
| Date | April 2019 |
| Language(s) of written materials | English |
| Creator(s) |
Collett, CF, Kitson, C, Baker, N, Steele-stallard, HB, Santrot, MV, Hutchinson, S, Horn, D and Alsford, S
|
| LSHTM Faculty/Department | Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection (-2019) |
| Participating Institutions | London School of Hygiene & Tropical Medicine, London, United Kingdom, University of Dundee, Dundee, United Kingdom. |
| Funders |
Project Funder Grant Number Funder URI |
| Date Deposited | 13 May 2019 16:16 |
| Last Modified | 08 Jul 2021 12:52 |
| Publisher | European Nucleotide Archive |
No files available. Please consult associated links.
